AFPSerum Institute of India and its Canadian partner Verity pharma on Friday received an approval from Health Canada to supply the Astrazeneca/Oxford vaccine to the country.
Health Canada received an application for authorization from AstraZeneca on October 1, 2020, and from Verity Pharmaceuticals Inc./Serum Institute of India (in partnership with AstraZeneca Canada Inc.) on January 23, 2021. After thorough, independent reviews of the evidence, the Department has determined that these vaccines meet Canada’s stringent safety, efficacy and quality requirements, the statement from the Canadian organisation said.
Canada has an agreement with AZ to receive 20 million doses. The approval to Verity Pharmaceuticals Inc./Serum Institute of India product has come on the basis of a comparability assessment with the AZ produced version of the vaccine.
Canada has signed up to receive the maximum number of vaccines in any country. However the vaccine roll out compared to the other OECD countries has been slow in the country. This is the third vaccine that Canada has approved, the other two vaccines that are under use in the country are by Pfizer and Moderna.
Canada is yet to sign any supply agreement with Serum Institute of India/Verity Pharma. However there are diplomatic negotiations going on at the highest political levels between both the countries for the vaccine supply. AZ has been facing supply delays in its several manufacturing facilities. This has led to delays from the company to supply to Europe.
Last week a spokesperson for Canada's Minister of Public Services and Procurement had told ET that Canada has not signed any procurement agreements with Serum Institute of India and the country’s principal supply will come from AstraZeneca's US manufacturing plant and from its partners in South Korea.
“Our principle supply of this vaccine will come through Canada’s bi-lateral agreement with the company for 20-million doses. We anticipate those doses will be manufactured in the US. Through the COVAX facility, we have been informed we will receive doses manufactured in South Korea. While no agreement with the Serum Institute of India has yet been finalized, such an agreement would be in addition to the above-mentioned doses”, said James Fitz-Morris Director Communications, Office of the Minister of Public Services and Procurement Canada to ET.
Health Canada received an application for authorization from AstraZeneca on October 1, 2020, and from Verity Pharmaceuticals Inc./Serum Institute of India (in partnership with AstraZeneca Canada Inc.) on January 23, 2021. After thorough, independent reviews of the evidence, the Department has determined that these vaccines meet Canada’s stringent safety, efficacy and quality requirements, the statement from the Canadian organisation said.
Canada has an agreement with AZ to receive 20 million doses. The approval to Verity Pharmaceuticals Inc./Serum Institute of India product has come on the basis of a comparability assessment with the AZ produced version of the vaccine.
Canada has signed up to receive the maximum number of vaccines in any country. However the vaccine roll out compared to the other OECD countries has been slow in the country. This is the third vaccine that Canada has approved, the other two vaccines that are under use in the country are by Pfizer and Moderna.
Canada is yet to sign any supply agreement with Serum Institute of India/Verity Pharma. However there are diplomatic negotiations going on at the highest political levels between both the countries for the vaccine supply. AZ has been facing supply delays in its several manufacturing facilities. This has led to delays from the company to supply to Europe.
Last week a spokesperson for Canada's Minister of Public Services and Procurement had told ET that Canada has not signed any procurement agreements with Serum Institute of India and the country’s principal supply will come from AstraZeneca's US manufacturing plant and from its partners in South Korea.
“Our principle supply of this vaccine will come through Canada’s bi-lateral agreement with the company for 20-million doses. We anticipate those doses will be manufactured in the US. Through the COVAX facility, we have been informed we will receive doses manufactured in South Korea. While no agreement with the Serum Institute of India has yet been finalized, such an agreement would be in addition to the above-mentioned doses”, said James Fitz-Morris Director Communications, Office of the Minister of Public Services and Procurement Canada to ET.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.